Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at Oakland, California and other locations
Dates
study started
estimated completion
Principal Investigator
by Margaret C Fang, MD
Photo of Margaret C Fang
Margaret C Fang

Description

Summary

Coronavirus disease 2019 (Covid-19) is now a leading cause of death among U.S. adults. In addition to profound respiratory and multi-organ failure, hypercoagulable states and venous thromboembolism (VTE) have been increasingly reported in patients with severe Covid-19. The aim of this study is evaluate the risk of VTE related to Covid-19 infection in a real-world community-based population.

Details

This is an observational study of adult (age ≥18 years) members enrolled in the Kaiser Permanente Northern California (KPNC) or Kaiser Permanente Southern California (KPSC) integrated healthcare delivery systems during the time period January 1, 2020 through December 31, 2020, (representing the first year of the Covid-19 pandemic) and diagnosed with incident Covid-19. The outcomes will be incident VTE and all-cause death, assessed through March 2021. The primary comparison will be the risk of post-hospitalization VTE between patients with Covid-19 compared with matched controls. Next, the risk of VTE associated with key patient subgroups, including by severity of Covid-19 disease, will be described.

Keywords

Venous Thromboembolism Covid19 Thromboembolism Laboratory test positive for SARS-CoV-2 virus

Eligibility

For people ages 18 years and up

Inclusion

  • Covid-19 diagnosis (defined as date of a positive laboratory test for SARS-CoV-2 virus) during the time period January 1, 2020 to December 31, 2020
  • Age >=18 years
  • Continuous pharmacy benefits and health plan membership for at least 12 months before the index date

Exclusion

• incomplete information on age and sex

Locations

  • Kaiser Permanente Northern California accepting new patients
    Oakland California 94612 United States
  • Kaiser Permanente Southern California accepting new patients
    Pasadena California 91101 United States

Lead Scientist at UCSF

  • Margaret C Fang, MD
    Margaret Fang is a clinician-investigator and the Research Director of the UCSF Division of Hospital Medicine. She also serves as the Medical Director of the UCSF Anticoagulation Clinic and the Director of the UCSF Academic Hospital Medicine Fellowship.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT04569344
Study Type
Observational
Last Updated